Induction of Heart Valve Lesions by Small-Molecule ALK5 Inhibitors

Mechanisms of TGF-β Signaling from Cell Membrane to the Nucleus

Shi, Y., & Massagué, J. (2003) · Cell · doi:10.1016/s0092-8674(03)00432-x · Cited by 5,860

TGFβ in Cancer

Massagué, J. (2008) · Cell · doi:10.1016/j.cell.2008.07.001 · Cited by 3,907

A small molecule–kinase interaction map for clinical kinase inhibitors

Fabian, M. A., Biggs, W., Treiber, D. K., Atteridge, C. E., Azimioara, M. D., Benedetti, M. G., Carter, T. A., Ciceri, P., Edeen, P. T., Floyd, M. B., et al. (2005) · Nature Biotechnology · doi:10.1038/nbt1068 · Cited by 1,923

Valvular heart disease associated with fenfluramine-phentermine

Connolly, H. M., Crary, J. L., McGoon, M. D., Hensrud, D. D., Edwards, B. S., Edwards, W. D., & Schaff, H. V. (1997) · New England Journal of Medicine · doi:10.1056/nejm199708283370901 · Cited by 1,632

TGFβ2 knockout mice have multiple developmental defects that are non-overlapping with other TGFβ knockout phenotypes

Sanford, L. P., Ormsby, I., Groot, A. C. G.-D., Sariola, H., Friedman, R., Boivin, G. P., Cardell, E. L., & Doetschman, T. (1997) · Development · doi:10.1242/dev.124.13.2659 · Cited by 1,447

TGFβ: the molecular Jekyll and Hyde of cancer

Bierie, B., & Moses, H. L. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1926 · Cited by 1,291

Valvular Heart Disease and the Use of Dopamine Agonists for Parkinson's Disease

Zanettini, R., Antonini, A., Gatto, G., Gentile, R., Tesei, S., & Pezzoli, G. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa054830 · Cited by 882

Physiological Actions and Clinical Applications of Transforming Growth Factor-β (TGF-β)

Roberts, A. B., & Sporn, M. B. (1993) · Growth Factors · doi:10.3109/08977199309029129 · Cited by 755

Dopamine Agonists and the Risk of Cardiac-Valve Regurgitation

Schade, R., Andersohn, F., Suissa, S., Haverkamp, W., & Garbe, E. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa062222 · Cited by 714

Transforming Growth Factor-β Signaling Through the Smad Pathway: Role in Extracellular Matrix Gene Expression and Regulation

Verrecchia, F., & Mauviel, A. (2002) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.2002.01641.x · Cited by 683

Dynamic allostery drives autocrine and paracrine TGF-β signaling

Jin, M., Seed, R., Cai, G., Shing, T., Wang, L., Ito, S., Cormier, A., Wankowicz, S. A. M., Jespersen, J. M., Baron, J. L., et al. (2024) · Cell · doi:10.1016/j.cell.2024.08.036 · Cited by 58

TGF-β Signaling Promotes Tissue Formation during Cardiac Valve Regeneration in Adult Zebrafish

Bensimon‐Brito, A., Ramkumar, S., Boezio, G. L. M., Guenther, S., Kuenne, C. T., Helker, C. S., Sánchez-Iranzo, H., Iloska, D., Piesker, J., Pullamsetti, S. S., et al. (2019) · Developmental Cell · doi:10.1016/j.devcel.2019.10.027 · Cited by 59

Safer approaches to therapeutic modulation of TGF-β signaling for respiratory disease

Lachapelle, P., Li, M., Douglass, J. A., & Stewart, A. G. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.02.010 · Cited by 54

Advances and Challenges in Targeting TGF-β Isoforms for Therapeutic Intervention of Cancer: A Mechanism-Based Perspective

Danielpour, D. (2024) · Pharmaceuticals · doi:10.3390/ph17040533 · Cited by 58

Therapeutic Approaches for Treating Pulmonary Arterial Hypertension by Correcting Imbalanced TGF-β Superfamily Signaling

André, P., Joshi, S. R., Briscoe, S. D., Alexander, M. J., Li, G., & Kumar, R. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2021.814222 · Cited by 53

Trial Watch—Small molecules targeting the immunological tumor microenvironment for cancer therapy

Buqué, A., Bloy, N., Aranda, F., Cremer, I., Eggermont, A. M. M., Fridman, W. H., Fucikova, J. P., Galon, J., Špíšek, R., Tartour, É., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1149674 · Cited by 50

Recent Advances in the Development of TGF-β Signaling Inhibitors for Anticancer Therapy

Lee, H.-J. (2020) · Journal of Cancer Prevention · doi:10.15430/jcp.2020.25.4.213 · Cited by 49

Targeting ER protein TXNDC5 in hepatic stellate cell mitigates liver fibrosis by repressing non-canonical TGFβ signalling

Hung, C., Su, T., Chen, Y.-T., Wu, Y., Chen, Y., Lin, S., Lin, S., & Yang, K. (2021) · Gut · doi:10.1136/gutjnl-2021-325065 · Cited by 49

Pharmaceutical treatment of bone loss: From animal models and drug development to future treatment strategies

Brent, M. B. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108383 · Cited by 52

Chronic activation of human cardiac fibroblasts in vitro attenuates the reversibility of the myofibroblast phenotype

Hall, C., Law, J. P., Reyat, J. S., Cumberland, M. J., Hang, S., Vo, N. T. N., Raniga, K., Weston, C. J., O’Shea, C., Townend, J., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-39369-y · Cited by 54

The TGF-β Pathway as an Emerging Target for Chagas Disease Therapy

de Araújo-Jorge, T. C., Waghabi, M. C., Bailly, S., & Feige, J. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2012.102 · Cited by 48

Genetic variants of Adam17 differentially regulate TGFβ signaling to modify vascular pathology in mice and humans

Kawasaki, K., Freimuth, J., Meyer, D. S., Lee, M. M., Tochimoto-Okamoto, A., Benzinou, M., Clermont, F. F., Wu, G., Roy, R., Letteboer, T. G. W., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1318761111 · Cited by 47

Potentiating CAR-T cell function in the immunosuppressive tumor microenvironment by inverting the TGF-β signal

Shen, Z., Che, X., Zhang, K., Bai, Y., & Deng, H. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.12.014 · Cited by 49

Hitting the Target! Challenges and Opportunities for TGF-β Inhibition for the Treatment of Cardiac fibrosis

Vistnes, M. (2024) · Pharmaceuticals · doi:10.3390/ph17030267 · Cited by 49

Hyaluronic Acid‐Nanocoated Bacteria Generate an Anti‐Inflammatory Tissue‐Repair Effect in Impaired Gut and Extraintestinal Organs

Deng, B., Lin, S., Wang, Y., Zhang, M., Shen, Y., Zhou, P., Shen, A., Wang, L., Ding, F. H., & Liu, J. (2024) · Advanced Materials · doi:10.1002/adma.202412783 · Cited by 51

Antifibrotic therapies for metabolic dysfunction-associated steatotic liver disease

Schwabe, R. F., Tacke, F., Sugimoto, A., & Friedman, S. L. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101421 · Cited by 52

Anti-Cancer Stem-like Cell Compounds in Clinical Development – An Overview and Critical Appraisal

Marcucci, F., Rumio, C., & Lefoulon, F. (2016) · Frontiers in Oncology · doi:10.3389/fonc.2016.00115 · Cited by 48

Yes-Associated Protein Targets the Transforming Growth Factor β Pathway to Mediate High-Fat/High-Sucrose Diet-induced Arterial Stiffness

Liu, Y., Li, M., Lv, X., Bao, K., Tian, X. Y., He, L., Shi, L., Zhu, Y., & Ai, D. (2022) · Circulation Research · doi:10.1161/circresaha.121.320464 · Cited by 43

Immunotherapy resistance in solid tumors: mechanisms and potential solutions

Lefler, D. S., Manobianco, S. A., & Bashir, B. (2024) · Cancer Biology & Therapy · doi:10.1080/15384047.2024.2315655 · Cited by 49

Anti-tumor activity of the TGF-β receptor kinase inhibitor galunisertib (LY2157299 monohydrate) in patient-derived tumor xenografts

Maier, A., Peille, A.-L., Vuaroqueaux, V., & Lahn, M. M. F. (2015) · Cellular Oncology · doi:10.1007/s13402-014-0210-8 · Cited by 43

68Ga-FAPI PET imaging monitors response to combined TGF-βR inhibition and immunotherapy in metastatic colorectal cancer

Li, K., Liu, W., Yu, H., Chen, J., Tang, W., Wang, J., Qi, M., Sun, Y., Xu, X., Zhang, J., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci170490 · Cited by 40

Targeting the transmembrane cytokine co-receptor neuropilin-1 in distal tubules improves renal injury and fibrosis

Li, Y., Wang, Z., Xu, H., Hong, Y., Shi, M., Hu, B., Wang, X., Ma, S., Wang, M., Cao, C., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-50121-6 · Cited by 40

Casein Kinase 1δ/ε Inhibitor, PF670462 Attenuates the Fibrogenic Effects of Transforming Growth Factor-β in Pulmonary Fibrosis

Keenan, C. R., Langenbach, S. Y., Jativa, F., Harris, T., Li, M., Chen, Q., Xia, Y., Gao, X., Schuliga, M. J., Jaffar, J., et al. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00738 · Cited by 39

Combined Inhibition of TGF-β1-Induced EMT and PD-L1 Silencing Re-Sensitizes Hepatocellular Carcinoma to Sorafenib Treatment

Shrestha, R., Prithviraj, P., Bridle, K. R., Crawford, D. H., & Jayachandran, A. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10091889 · Cited by 38

TGF-β as a therapeutic target in the infarcted and failing heart: cellular mechanisms, challenges, and opportunities

Frangogiannis, N. G. (2024) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2024.2316735 · Cited by 39

ATM Regulates Differentiation of Myofibroblastic Cancer-Associated Fibroblasts and Can Be Targeted to Overcome Immunotherapy Resistance

Mellone, M., Piotrowska, K., Venturi, G., James, L., Bzura, A., Lopez, M. A., James, S., Wang, C., Ellis, M. J., Hanley, C. J., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-22-0435 · Cited by 36

Copper chelation suppresses epithelial-mesenchymal transition by inhibition of canonical and non-canonical TGF-β signaling pathways in cancer

Poursani, E. M., Mercatelli, D., Raninga, P. V., Bell, J. L., Saletta, F., Kohane, F. V., Neumann, D., Ye, Z., Rouaen, J. R. C., Jue, T. R., et al. (2023) · Cell & Bioscience · doi:10.1186/s13578-023-01083-7 · Cited by 38

Bone morphogenetic protein 1.3 inhibition decreases scar formation and supports cardiomyocyte survival after myocardial infarction

Vukičević, S., Colliva, A., Kufner, V., Martinelli, V. C., Moimas, S., Vodret, S., Rumenović, V., Milošević, M., Brkljačić, B., Delić-Brkljačić, D., et al. (2022) · Nature Communications · doi:10.1038/s41467-021-27622-9 · Cited by 35

Cold Atmospheric Plasma as an Adjunct to Immunotherapy for Glioblastoma Multiforme

Almeida, N. D., Klein, A. L., Hogan, E. A., Terhaar, S. J., Kedda, J. N., Uppal, P., Sack, K., Keidar, M., & Sherman, J. H. (2019) · World Neurosurgery · doi:10.1016/j.wneu.2019.06.209 · Cited by 34

Mutations in SKI in Shprintzen–Goldberg syndrome lead to attenuated TGF-β responses through SKI stabilization

Gori, I., George, R., Purkiss, A. G., Strohbuecker, S., Randall, R. A., Ogrodowicz, R. W., Carmignac, V., Faivre, L. O., Joshi, D., Kjær, S., et al. (2021) · eLife · doi:10.7554/elife.63545 · Cited by 32

Enhanced Effectivity of an ALK5-Inhibitor after Cell-Specific Delivery to Hepatic Stellate Cells in Mice with Liver Injury

van Beuge, M. M., Prakash, J., Lacombe, M., Post, E., Reker‐Smit, C., Beljaars, L., & Poelstra, K. (2013) · PLoS ONE · doi:10.1371/journal.pone.0056442 · Cited by 32

Preclinical Evaluation of AZ12601011 and AZ12799734, Inhibitors of Transforming Growth Factor β Superfamily Type 1 Receptors

Spender, L. C., Ferguson, G. J., Hughes, G. D., Davies, B. R., Goldberg, F. W., Herrera, B. M., Taylor, R. G., Strathearn, L. S., Sansom, O. J., Barry, S. T., et al. (2018) · Molecular Pharmacology · doi:10.1124/mol.118.112946 · Cited by 32

TGF-β in correlation with tumor progression, immunosuppression and targeted therapy in colorectal cancer

Singh, S. P., Gouri, V., & Samant, M. (2023) · Medical Oncology · doi:10.1007/s12032-023-02204-5 · Cited by 31

Nonclinical Safety Evaluation of a Transforming Growth Factor β Receptor I Kinase Inhibitor in Fischer 344 Rats and Beagle Dogs

Stauber, A. J. (2014) · Journal of Clinical Toxicology · doi:10.4172/2161-0495.196 · Cited by 31

Discovery of BMS-986260, a Potent, Selective, and Orally Bioavailable TGFβR1 Inhibitor as an Immuno-oncology Agent

Velaparthi, U., Darne, C. P., Warrier, J., Liu, P., Rahaman, H., Augustine‐Rauch, K. A., Parrish, K. E., Yang, Z., Swanson, J., Brown, J. G., et al. (2020) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.9b00552 · Cited by 31

Therapeutic Delivery of Pip4k2c‐Modified mRNA Attenuates Cardiac Hypertrophy and Fibrosis in the Failing Heart

Magadum, A., Singh, N., Kurian, A. A., Sharkar, M. T. K., Sultana, N., Chepurko, E., Kaur, K., Żak, M. M., Hadas, Y., Lebeche, D., et al. (2021) · Advanced Science · doi:10.1002/advs.202004661 · Cited by 30

Bronchial epithelial cells are rendered insensitive to glucocorticoid transactivation by transforming growth factor-β1

Keenan, C. R., Mok, S.-L., Harris, T., Xia, Y., Salem, S., & Stewart, A. G. (2014) · Respiratory Research · doi:10.1186/1465-9921-15-55 · Cited by 30

Is personalised medicine the key to heterogeneity in idiopathic pulmonary fibrosis?

Clarke, D. L., Murray, L. A., Crestani, B., & Sleeman, M. A. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.09.010 · Cited by 31

Nanotechnology‐Based CAR‐T Strategies for Improving Efficacy and Safety of Tumor Immunotherapy

Wang, X., Meng, F., Yen, Y., Li, R., & Liu, B. (2020) · Advanced Functional Materials · doi:10.1002/adfm.202004713 · Cited by 33

A tumor-specific mechanism of T reg enrichment mediated by the integrin αvβ8

Seed, R., Kobayashi, K., Ito, S., Takasaka, N., Cormier, A., Jespersen, J. M., Publicover, J., Trilok, S., Combes, A. J., Chew, N. W., et al. (2021) · Science Immunology · doi:10.1126/sciimmunol.abf0558 · Cited by 31

Specific Activin Receptor–Like Kinase 3 Inhibitors Enhance Liver Regeneration

Tsugawa, D., Oya, Y., Masuzaki, R., Ray, K. C., Engers, D. W., Dib, M. J., Do, N., Kuramitsu, K., Ho, K. J., Frist, A. Y., et al. (2014) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.114.216903 · Cited by 29

Hitting More Birds with a Stone: Impact of TGF-β on ILC Activity in Cancer

Fionda, C., Stabile, H., Cerboni, C., Soriani, A., Gismondi, A., Cippitelli, M., & Santoni, A. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9010143 · Cited by 31

BMPR1A promotes ID2–ZEB1 interaction to suppress excessive endothelial to mesenchymal transition

Lee, H., Adachi, T., Pak, B., Park, S., Hu, X., Choi, W., Kowalski, P. S., Chang, C., Clapham, K. R., Lee, A., et al. (2022) · Cardiovascular Research · doi:10.1093/cvr/cvac159 · Cited by 28

The long noncoding RNA THBS1-AS1 promotes cardiac fibroblast activation in cardiac fibrosis by regulating TGFBR1

Zhou, J., Tian, G., Quan, Y., Kong, Q., Huang, F., Li, J., Wu, W.-C., Tang, Y., Zhou, Z., & Liu, X. (2023) · JCI Insight · doi:10.1172/jci.insight.160745 · Cited by 28

Immunotherapy for glioblastoma

Weiß, T., Weller, M., & Roth, P. (2015) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000249 · Cited by 27

It’s Time to Shift the Paradigm: Translation and Clinical Application of Non-αvβ3 Integrin Targeting Radiopharmaceuticals

Kossatz, S., Beer, A. J., & Notni, J. (2021) · Cancers · doi:10.3390/cancers13235958 · Cited by 28

An antibody that inhibits TGF-β1 release from latent extracellular matrix complexes attenuates the progression of renal fibrosis

Jackson, J., Streich, F. C., Pal, A., Coricor, G., Boston, C., Brueckner, C., Canonico, K., Chapron, C., Cote, S. M., Dagbay, K. B., et al. (2024) · Science Signaling · doi:10.1126/scisignal.adn6052 · Cited by 30

Nonclinical Development of SRK-181: An Anti-Latent TGFβ1 Monoclonal Antibody for the Treatment of Locally Advanced or Metastatic Solid Tumors

Welsh, B. T., Faucette, R., Bilic, S., Martin, C. J., Schürpf, T., Chen, D. J., Nicholls, S. B., Lansita, J. A., & Kalra, A. V. (2021) · International Journal of Toxicology · doi:10.1177/1091581821998945 · Cited by 28

Design, synthesis and optimization of 7-substituted-pyrazolo[4,3-b]pyridine ALK5 (activin receptor-like kinase 5) inhibitors

Sabat, M. P., Wang, H., Scorah, N., Lawson, J. D., Atienza, J., Kamran, R., Hixon, M. S., & Dougan, D. R. (2017) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2017.03.026 · Cited by 25

The c-Abl-RACK1-FAK signaling axis promotes renal fibrosis in mice through regulating fibroblast-myofibroblast transition

Bao, Q., Wang, A., Hong, W., Wang, Y., Li, B., He, L., Yuan, X., & Ma, G. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01603-z · Cited by 27

Inhibition of TGFβ1 and TGFβ3 promotes hematopoiesis in Fanconi anemia

Rodríguez, A., Yang, C., Furutani, E., Teresa, B. G., Velázquez, M., Filiatrault, J., Sambel, L. A., Phan, T., Flores-Guzmán, P., Sánchez, S., et al. (2020) · Experimental Hematology · doi:10.1016/j.exphem.2020.11.002 · Cited by 24

Network model‐based screen for FDA‐approved drugs affecting cardiac fibrosis

Zeigler, A. C., Chandrabhatla, A. S., Christiansen, S. L. M., Nelson, A. R., Holmes, J. W., & Saucerman, J. J. (2021) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12599 · Cited by 24

Nitazoxanide inhibits acetylated KLF5-induced bone metastasis by modulating KLF5 function in prostate cancer

Huang, Q., Liu, M.-C., Zhang, D., Lin, B.-B., Fu, X., Zhang, Z., Zhang, B., & Dong, J. (2023) · BMC Medicine · doi:10.1186/s12916-023-02763-4 · Cited by 26

Optimization of Selectivity and Pharmacokinetic Properties of Salt-Inducible Kinase Inhibitors that Led to the Discovery of Pan-SIK Inhibitor GLPG3312

Laı̈b, T., Peixoto, C., Desroy, N., Lemos, E. D., Bonnaterre, F., Bienvenu, N., Picolet, O., Sartori, E., Bucher, D., López‐Ramos, M., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01428 · Cited by 24

Functional recovery of natural killer cell activity by nanoparticle‐mediated delivery of transforming growth factor beta 2 small interfering RNA

Adjei, I. M., Jordan, J. C., Tu, N., Trinh, T. L., Kandell, W. M., Wei, S., & Sharma, B. (2019) · Journal of Interdisciplinary Nanomedicine · doi:10.1002/jin2.63 · Cited by 24

Attenuation of Dupuytren’s fibrosis via targeting of the STAT1 modulated IL-13Rα1 response

Akbar, M., Melchor, E. G., Chilaka, S., Little, K. J., Sood, S., Reilly, J. H., Liew, F. Y., McInnes, I. B., & Millar, N. L. (2020) · Science Advances · doi:10.1126/sciadv.aaz8272 · Cited by 23

The role of transforming growth factor‐beta in immune suppression and chronic inflammation of squamous cell carcinomas

Strait, A. A., & Wang, X. (2020) · Molecular Carcinogenesis · doi:10.1002/mc.23196 · Cited by 22

TGFβ1 neutralization displays therapeutic efficacy through both an immunomodulatory and a non-immune tumor-intrinsic mechanism

Canè, S., Snick, J. V., Uyttenhove, C., Pilotte, L., & den Eynde, B. J. V. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001798 · Cited by 24

A strategic expression method of miR-29b and its anti-fibrotic effect based on RNA-sequencing analysis

Fan, X., Gao, Y., Zhang, X., Lughmani, H. Y., Kennedy, D. J., Haller, S. T., Pierre, S. V., Shapiro, J. I., & Tian, J. (2020) · PLoS ONE · doi:10.1371/journal.pone.0244065 · Cited by 21

Tracking a TGF-β activator in vivo: sensitive PET imaging of αvβ8-integrin with the Ga-68-labeled cyclic RGD octapeptide trimer Ga-68-Triveoctin

Quigley, N. G., Steiger, K., Richter, F., Weichert, W., Hoberück, S., Kotzerke, J., & Notni, J. (2020) · EJNMMI Research · doi:10.1186/s13550-020-00706-1 · Cited by 21

Identification of novel biomarkers for arthrofibrosis after total knee arthroplasty in animal models and clinical patients

Chen, X., Wang, Z., Huang, Y., Deng, W., Zhou, Y., & Chu, M. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103486 · Cited by 20

The treatment strategy of connective tissue disease associated pulmonary arterial hypertension: Evolving into the future

Zhao, J., Wang, Q., Deng, X., Qian, J., Tian, Z., Liu, Y., Li, M., & Zeng, X. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108192 · Cited by 19

PF-06952229, a selective TGF-β-R1 inhibitor: preclinical development and a first-in-human, phase I, dose-escalation study in advanced solid tumors

Yap, T. A., Choudhury, A. D., Hamilton, E. P., Rosen, L. S., Stratton, K. L., Gordon, M. S., Schaer, D., Liu, L., Zhang, L., Mittapalli, R. K., et al. (2024) · ESMO Open · doi:10.1016/j.esmoop.2024.103653 · Cited by 20

Targeting TGFβ superfamily ligand accessory proteins as novel therapeutics for chronic lung disorders

Budd, D. C., & Holmes, A. M. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.06.001 · Cited by 21

Targeting Intercellular Communication in the Bone Microenvironment to Prevent Disseminated Tumor Cell Escape from Dormancy and Bone Metastatic Tumor Growth

Kreps, L. M., & Addison, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22062911 · Cited by 22

Periostin increased by mechanical stress upregulates interleukin‐6 expression in the ligamentum flavum

Yabu, A., Suzuki, A., Hayashi, K., Hori, Y., Terai, H., Orita, K., Habibi, H., Salimi, H., Kono, H., Toyoda, H., et al. (2022) · The FASEB Journal · doi:10.1096/fj.202200917rr · Cited by 19

Addressing Natural Killer Cell Dysfunction and Plasticity in Cell-Based Cancer Therapeutics

Coyle, K. M., Hawke, L. G., & Ormiston, M. L. (2023) · Cancers · doi:10.3390/cancers15061743 · Cited by 19

Animal models of organic heart valve disease

Roosens, B., Bala, G., Droogmans, S., Camp, G. V., Breyne, J., & Cosyns, B. (2012) · International Journal of Cardiology · doi:10.1016/j.ijcard.2012.03.065 · Cited by 19

A narrative review of the relationship between TGF-β signaling and gynecological malignant tumor

Luo, F., Huang, Y., Li, Y., Zhao, X., Xie, Y., Zhang, Q., Mei, J., & Liu, X. (2021) · Annals of Translational Medicine · doi:10.21037/atm-21-4879 · Cited by 18

CRISPR-Knockout Screen Identifies Dmap1 as a Regulator of Chemically Induced Reprogramming and Differentiation of Cardiac Progenitors

Yu, J., Palano, G., Lim, C., Moggio, A., Drowley, L., Plowright, A. T., Bohlooly‐Y, M., Rosen, B. S., Hansson, E. M., Wang, Q., et al. (2019) · Stem Cells · doi:10.1002/stem.3012 · Cited by 18

Targeting the immunity protein kinases for immuno-oncology

Yuan, X., Wu, H., Bu, H., Zhou, J., & Zhang, H. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.11.072 · Cited by 17

Targeting TGF-β: a promising strategy for cancer therapy

Himani, Kaur, C., Kumar, R., Mishra, R., & Singh, G. (2025) · Medical Oncology · doi:10.1007/s12032-025-02667-8 · Cited by 16

Integrated and translational nonclinical in vivo cardiovascular risk assessment: Gaps and opportunities

Berridge, B. R., Hoffmann, P., Turk, J. R., Sellke, F. W., Gintant, G. A., Hirkaler, G., Dreher, K. L., Schultze, A. E., Walker, D. B., Edmunds, N., et al. (2012) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2012.09.007 · Cited by 16

IL-11/IL-11R signal inhibition by 9MW3811 remodels immune tumor microenvironment and enhances anti-tumor efficacy of PD-1 blockade

Zhang, C., Jiao, S., Zeng, D., Jiang, W. G., Wang, R., Zheng, B., Wang, M., Wang, S., & Gui, X. (2025) · npj Precision Oncology · doi:10.1038/s41698-025-00913-w · Cited by 15

Tissue regeneration: Unraveling strategies for resolving pathological fibrosis

Li, J., Wang, S., Yuan, J., Mao, X., Wang, X., Zhang, L., Dong, Q., Chen, Z., Wang, Y., & Tang, N. (2025) · Cell stem cell · doi:10.1016/j.stem.2025.10.002 · Cited by 19

In Chagas disease, transforming growth factor beta neutralization reduces Trypanosoma cruzi infection and improves cardiac performance

Ferreira, R. R., de Souza, E. M., Vilar-Pereira, G., Degrave, W., Abreu, R. D. S., Meuser-Batista, M., Ferreira, N. V. C., Ledbeter, S., Barker, R. H., Bailly, S., et al. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.1017040 · Cited by 15

GPCRs and fibroblast heterogeneity in fibroblast‐associated diseases

Dwivedi, N. V., Datta, S., El‐Kersh, K., Sadikot, R. T., Ganti, A. K., Batra, S. K., & Jain, M. (2023) · The FASEB Journal · doi:10.1096/fj.202301091 · Cited by 16

Cellular and molecular mechanisms driving cardiac tissue fibrosis: On the precipice of personalized and precision medicine

Hassanabad, A. F., Zarzycki, A. N., & Fedak, P. W. M. (2024) · Cardiovascular Pathology · doi:10.1016/j.carpath.2024.107635 · Cited by 18

Molecular Pathology

Oyejide, L., Mendes, O. R., & Mikaelian, I. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-803620-4.00016-5 · Cited by 15

Late‐Stage Functionalization by Chan–Lam Amination: Rapid Access to Potent and Selective Integrin Inhibitors

Robinson, H., Oatley, S. A., Rowedder, J. E., Slade, P., Macdonald, S. J. F., Argent, S. P., Hirst, J. D., McInally, T., & Moody, C. J. (2020) · Chemistry - A European Journal · doi:10.1002/chem.202001059 · Cited by 15

Design, synthesis and optimization of novel Alk5 (activin-like kinase 5) inhibitors

Wang, H., Lawson, J. D., Scorah, N., Kamran, R., Hixon, M. S., Atienza, J., Dougan, D. R., & Sabat, M. P. (2016) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.07.030 · Cited by 15

Development of the Novel Bifunctional Fusion Protein BR102 That Simultaneously Targets PD-L1 and TGF-β for Anticancer Immunotherapy

Wu, Z.-H., Li, N., Gao, Z., Chen, G., Nie, L., Zhou, Y., Jiang, M.-Z., Chen, Y., Chen, J., Mei, X.-F., et al. (2022) · Cancers · doi:10.3390/cancers14194964 · Cited by 13

Lysine acetyltransferase 14 mediates TGF-β-induced fibrosis in ovarian endometrioma via co-operation with serum response factor

Gong, Y., Liu, M., Zhang, Q., Li, J., Cai, H., Ran, J., Ma, L., Ma, Y., & Quan, S. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05243-2 · Cited by 16

Good and bad sides of TGFβ-signaling in myocardial infarction

Euler, G. (2015) · Frontiers in Physiology · doi:10.3389/fphys.2015.00006 · Cited by 14

Discovery of Selective Transforming Growth Factor β Type II Receptor Inhibitors as Antifibrosis Agents

Miwa, S., Yokota, M., Ueyama, Y., Maeda, K., Ogoshi, Y., Seki, N., Ogawa, N., Nishihata, J., Nomura, A., Adachi, T., et al. (2021) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.0c00679 · Cited by 14

Adaptive mechanisms of resistance to anti-neoplastic agents

Ferreira, B. I., Lie, M. K., Engelsen, A. S. T., Machado, S., Link, W., & Lorens, J. B. (2016) · MedChemComm · doi:10.1039/c6md00394j · Cited by 14

Intermittent dosing of the transforming growth factor beta receptor 1 inhibitor, BMS‐986260, mitigates class‐based cardiovascular toxicity in dogs but not rats

Rak, G. D., White, M. R., Augustine‐Rauch, K. A., Newsome, C., Graziano, M. J., & Schulze, G. E. (2020) · Journal of Applied Toxicology · doi:10.1002/jat.3954 · Cited by 14

Disulfiram prevents collagen crosslinking and inhibits renal fibrosis by inhibiting lysyl oxidase enzymes

Saifi, M. A., Shaikh, A. S., Kaki, V. R., & Godugu, C. (2022) · Journal of Cellular Physiology · doi:10.1002/jcp.30717 · Cited by 13

Phosphorylation of ΔNp63α via a Novel TGFβ/ALK5 Signaling Mechanism Mediates the Anti-Clonogenic Effects of TGFβ

Cherukuri, P., DeCastro, A., Balboni, A., Downey-Kopyscinski, S. L., Liu, J. Y., Hutchinson, J. A., & DiRenzo, J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0050066 · Cited by 13

Lung-restricted ALK5 inhibition avoids systemic toxicities associated with TGFβ pathway inhibition

Maher, J. M., Zhang, R., Palanisamy, G. S., Perkins, K., Liu, L., Brassil, P. J., McNamara, A., Lo, A., Hughes, A. D., Kanodia, J., et al. (2022) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2022.115905 · Cited by 13

Transforming growth factor-ß as a therapeutic target for the cardiac damage of Chagas disease

Waghabi, M. C., Ferreira, R. R., Abreu, R. D. S., Degrave, W., de Souza, E. M., Bailly, S., Feige, J., & de Araújo-Jorge, T. C. (2022) · Memórias do Instituto Oswaldo Cruz · doi:10.1590/0074-02760210395 · Cited by 13

Fibroblasts and platelets: a face-to-face dialogue at the heart of cardiac fibrosis

Dufeys, C., Bodart, J., Bertrand, L., Beauloye, C., & Horman, S. (2024) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00559.2023 · Cited by 13

The role and mechanism of TXNDC5 in disease progression

Jiao, M., Zhang, Y., Xie, S., & Xu, B. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1354952 · Cited by 12

Triggering AHR resolves TGF-β1 induced fibroblast activation and promotes AT1 cell regeneration in alveolar organoids

Hagan, A. S., Williams, S., Mathison, C. J. N., Yan, S., Nguyen, B., Federe, G. C., Kuzu, G., Siefert, J. C., Hampton, J., Chichkov, V., et al. (2025) · Communications Biology · doi:10.1038/s42003-025-08446-5 · Cited by 12

The Role of TGF-β, Activin and Follistatin in Inflammatory Bowel Disease

Esfahani, N. H., & Day, A. S. (2023) · Gastrointestinal Disorders · doi:10.3390/gidisord5020015 · Cited by 11

Design and Synthesis of Inhibitors of the E3 Ligase SMAD Specific E3 Ubiquitin Protein Ligase 1 as a Treatment for Lung Remodeling in Pulmonary Arterial Hypertension

Shaw, D. E., Smith, N. J., Beerli, R., Cotesta, S., D’Alessandro, P.-L., Edwards, A.-M., Lattmann, R., Lizos, D. E., Pulz, R., Rooney, L., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00229 · Cited by 10

High Hematocrit Resulting from Administration of Erythropoiesis-stimulating Agents Is Not Fully Predictive of Mortality or Toxicities in Preclinical Species

Andrews, D. A., Pyrah, I. T. G., Boren, B. M., Tannehill‐Gregg, S. H., & Lightfoot-Dunn, R. M. (2013) · Toxicologic Pathology · doi:10.1177/0192623313486317 · Cited by 11

Shared molecular, cellular, and environmental hallmarks in cardiovascular disease and cancer: Any place for drug repurposing?

Avolio, E., Bassani, B., Campanile, M., Mohammed, K. A. K., Muti, P. C., Bruno, A., Spinetti, G., & Madeddu, P. R. (2024) · Pharmacological Reviews · doi:10.1016/j.pharmr.2024.100033 · Cited by 9

Integrated stress response-mediated metabolic reprogramming drives hepatic stellate cell activation and liver fibrosis via the noncanonical EIF3d-ATF4-S100P signaling pathway

Yang, S., Zhang, H., Sun, X., Chen, Z., Nie, Z., Li, Y., Liu, X., Kong, Y., Wang, Z., Zai, W., et al. (2025) · Redox Biology · doi:10.1016/j.redox.2025.103905 · Cited by 9

TGF-β-mediated suppression of NK cell function and targeting strategies in tumor immunotherapy

Wang, B., & Bi, J. (2026) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2026.105141 · Cited by 10

The effect of transforming growth factor-beta type I receptor kinase inhibition on the heart valves of Sprague-Dawley rats

Maratea, K. A. (2009) · Purdue e-Pubs (Purdue University System)

A Constitutive Mutation ofALK5Disrupts Cardiac Looping and Morphogenesis in Mice

Charng, M., Frenkel, P. A., Lin, Q., Yumada, M., Schwartz, R. J., Olson, E. N., Overbeek, P. A., & Schneider, M. D. (1998) · Developmental Biology · doi:10.1006/dbio.1998.8905 · Cited by 40

Inhibition of ALK5 Signaling Induces Physeal Dysplasia in Rats

Frazier, K. S., Thomas, R. A., Scicchitano, M. S., Mirabile, R. C., Boyce, R. W., Zimmerman, D. M., Grygielko, E. T., Nold, J. B., DeGouville, A.-C., Huet, S., et al. (2007) · Toxicologic Pathology · doi:10.1080/01926230701198469 · Cited by 49

Signaling via the Tgf-β type I receptor Alk5 in heart development

Sridurongrit, S., Larsson, J., Schwartz, R. J., Ruiz‐Lozano, P., & Kaartinen, V. (2008) · Developmental Biology · doi:10.1016/j.ydbio.2008.07.038 · Cited by 158

Activin receptor-like kinase 2 and Smad6 regulate epithelial–mesenchymal transformation during cardiac valve formation

Desgrosellier, J. S., Mundell, N. A., McDonnell, M. A., Moses, H. L., & Barnett, J. V. (2005) · Developmental Biology · doi:10.1016/j.ydbio.2004.12.037 · Cited by 88